Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | F2 | P00734 | 6/20 | 0.41 |
| ▸ | F10 | P00742 | 6/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21609309 | 0.88 | F10 (0.43) | F2F10PRSS1LMNAL3MBTL1 | |
| SCHEMBL30947795 | 0.88 | F10 (0.43) | F2F10PRSS1LMNAL3MBTL1 | |
| SCHEMBL6478945 | 0.87 | ALDH1A1 (0.38) | KCNA5F2F10PRSS1MEN1 | |
| SCHEMBL7680353 | 0.86 | F2 (0.42) | F2F10PRSS1MEN1LMNA | |
| SCHEMBL7682611 | 0.85 | F2 (0.41) | F2F10PRSS1ALDH1A1CYP3A4 | |
| SCHEMBL7688540 | 0.85 | L3MBTL1 (0.48) | F2F10PRSS1MEN1KMT2A | |
| SCHEMBL6478745 | 0.85 | ALDH1A1 (0.41) | F2F10PRSS1MEN1LMNA | |
| SCHEMBL30947796 | 0.85 | ALDH1A1 (0.41) | F2F10PRSS1MEN1LMNA | |
| SCHEMBL7688672 | 0.85 | MEN1 (0.49) | MEN1LMNAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL29921355 | 0.84 | ALDH1A1 (0.51) | KCNA5KMT2AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861530-B2 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2005-03-01 | — | — | US | disclosed |
| US-6492392-B1 | INHIBITING TUMOR CELL PROLIFERATION | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| US-20020137770-A1 | Piperidine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-26 | — | — | US | disclosed |
| WO-2001085716-A1 | 2-PIPERIDONE COMPOUNDS FOR THE TREATMENT OF CANCER | KYOWA HAKKO KOGYO CO., LTD (JP) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137770-A1 | Piperidine derivatives | CIP2A, PARP2, TP53 | KCNA5 1720/4885F2 4856/4885F10 4834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.